ClinicalTrials.gg
CompletedNCT05615363Updated Oct 20, 2025Results posted

A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])

A Phase 2 interventional study of OPC 131461 10mg group and OPC 131461 5mg group in Cardiac Edema (CHF), sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2025-10-20.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
157
Allocation
Randomized
Ages
18 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 17 studies in Heart Failure by Otsuka Holdings Co., Ltd. — none open to participants now, 1 under way, none of them phase 3. Heart Failure · Otsuka Holdings Co., Ltd..

Enrollment
5th of 16
157 · median 81
Started
2023
with 1 other
Phase 2
6 of 17
none open now
Registered
15th of 17
by date

Among the 17 studies in Heart Failure by Otsuka Holdings Co., Ltd., this one is the 5th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2023, is one of 6 in phase 2, and was the 15th registered.

Heart Failure

6,339 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

None of the 17 studies in Heart Failure by Otsuka Holdings Co., Ltd. is open now. The open studies under Heart Failure, anywhere →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 89 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies in Heart Failure by Otsuka Holdings Co., Ltd. as a file.
02

Study summary

To investigate the dose response in respect of weight decrease following repeated oral administration of OPC-131461 at 1, 2, 5, and 10 mg or placebo in patients with CHF with volume overload despite having received diuretics other than vasopressin antagonists

03

Conditions studied

  • Cardiac Edema (CHF)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with CHF with lower limb edema, pulmonary congestion, or jugular venous distension due to volume overload.
  • Subjects undergoing any of the following diuretic therapies

    • Loop diuretics at a dosage equivalent to 40 mg/day or more of furosemide tablet/fine granule
    • Concomitant administration of a loop diuretic and a thiazide diuretic (including similar drugs) at any doses
    • Concomitant administration of a loop diuretic and a mineralocorticoid receptor antagonist or potassium-sparing diuretic at any doses
  • Subjects who were currently hospitalized or who are able to be hospitalized

Exclusion criteria

Exclusion Criteria:

  • Subjects with acute heart failure
  • Subjects with an assisted circulation device
  • Subjects who cannot sense thirst or who have difficulty in ingesting water
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
157 participants (actual)

Study arms

  • Experimental
    OPC 131461 10mg group

    OPC-131461 5 mg tablet x 2

    Drug: OPC 131461 10mg group

  • Experimental
    OPC 131461 5mg group

    OPC-131461 5 mg tablet and placebo tablet

    Drug: OPC 131461 5mg group

  • Experimental
    OPC 131461 2mg group

    OPC-131461 1 mg tablet x 2

    Drug: OPC 131461 2mg group

  • Experimental
    OPC 131461 1mg group

    OPC-131461 1 mg tablet and placebo tablet

    Drug: OPC 131461 1mg group

  • Placebo comparator
    Placebo

    Placebo tablet

    Drug: Placebo

Interventions

  • DrugOPC 131461 10mg group

    OPC-131461 5 mg tablet x 2,once-daily oral administration for 14 days

  • DrugOPC 131461 5mg group

    OPC-131461 5 mg tablet and placebo tablet,once-daily oral administration for 14 days

  • DrugOPC 131461 2mg group

    OPC-131461 1 mg tablet x 2,once-daily oral administration for 14 days

  • DrugOPC 131461 1mg group

    OPC-131461 1 mg tablet and placebo tablet,once-daily oral administration for 14 days

  • DrugPlacebo

    Placebo tablet,once-daily oral administration for 14 days

06

What researchers measure

Primary outcomes

  1. Change in Body Weight From Baseline to Last Assessment Time Point (the Day After IMP Administration) by Day 8

    Calculate the change in body weight from the baseline up to Day 8 (kg)

    Time frame: Baseline, Day 8

Secondary outcomes

  1. Change in Body Weight From Baseline to Last Assessment Time Point (the Day After IMP Administration) by Day 15

    Calculate the percentage change in body weight from the baseline up to last assessment time point (the day after IMP administration) by Day 15 (%)

    Time frame: Baseline, Day15

  2. Improvement of or Change in Congestive Findings ( Lower Limb Edema ) From Baseline to Last Assessment Time Point (the Day of IMP Administration) by Day 7

    The tibial margins or acrotarsia in a sitting position will be examined to assess the severity of edema according to the criteria in 0 : Absent, No pitting observed at all, 1:Mild,Slight pitting observed, 2:Moderate, Pitting observed, 3 : Severe,Apparent edema. Improvement rates (percentages of subjects who have symptoms at baseline and show markedly improved or improved after IMP administration) and resolution rates (percentages of subjects who have symptoms at baseline and no symptoms after IMP administration) at the last assessment time point (the day of IMP administration) by Day 7.

    Time frame: Baseline, Day7

  3. Improvement of or Change in Congestive Findings ( Pulmonary Congestion ) From Baseline to Last Assessment Time Point (the Day of IMP Administration) by Day 7

    The severity of pulmonary congestion will be determined according to the criteria in 0 : Absent, No congestion, 1:Mild,Pulmonary venous congestion, 2:Moderate, Interstitial pulmonary edema, 3 : Severe, Alveolar pulmonary edema. Improvement rates (percentages of subjects who have symptoms at baseline and show markedly improved or improved after IMP administration) and resolution rates (percentages of subjects who have symptoms at baseline and no symptoms after IMP administration) at the last assessment time point (the day of IMP administration) by Day 7.

    Time frame: Baseline, Day7

07

Results

Posted Oct 20, 2025

Participant flow

Participant flow — Overall Study
MilestoneMaterial AMaterial BMaterial CMaterial DPlacebo
Started3132313330
Completed2728222925
Not completed44945
Withdrew: Adverse event04431
Withdrew: Physician decision20413
Withdrew: Protocol violation20001
Withdrew: Withdrawal by subject00100

Outcome measures

PrimaryChange in Body Weight From Baseline to Last Assessment Time Point (the Day After IMP Administration) by Day 8

Calculate the change in body weight from the baseline up to Day 8 (kg)

Time frame:
Baseline, Day 8
Reported as:
Least squares mean · kg
Change in Body Weight From Baseline to Last Assessment Time Point (the Day After IMP Administration) by Day 8
kgMaterial AMaterial BMaterial CMaterial DPlacebo
Change in Body Weight From Baseline to Last Assessment Time Point (the Day After IMP Administration) by Day 8-1.96 (-2.50 to -1.42)-1.74 (-2.28 to -1.20)-1.4 (-1.94 to -0.85)-1.84 (-2.36 to -1.31)-1.17 (-1.72 to -0.62)
SecondaryChange in Body Weight From Baseline to Last Assessment Time Point (the Day After IMP Administration) by Day 15

Calculate the percentage change in body weight from the baseline up to last assessment time point (the day after IMP administration) by Day 15 (%)

Time frame:
Baseline, Day15
Reported as:
Least squares mean · kg
Change in Body Weight From Baseline to Last Assessment Time Point (the Day After IMP Administration) by Day 15
kgMaterial AMaterial BMaterial CMaterial DPlacebo
Change in Body Weight From Baseline to Last Assessment Time Point (the Day After IMP Administration) by Day 15-2.12 (-2.80 to -1.44)-2.11 (-2.79 to -1.43)-1.72 (-2.41 to -1.03)-1.87 (-2.53 to -1.21)-1.38 (-2.07 to -0.69)
SecondaryImprovement of or Change in Congestive Findings ( Lower Limb Edema ) From Baseline to Last Assessment Time Point (the Day of IMP Administration) by Day 7

The tibial margins or acrotarsia in a sitting position will be examined to assess the severity of edema according to the criteria in 0 : Absent, No pitting observed at all, 1:Mild,Slight pitting observed, 2:Moderate, Pitting observed, 3 : Severe,Apparent edema. Improvement rates (percentages of subjects who have symptoms at baseline and show markedly improved or improved after IMP administration) and resolution rates (percentages of subjects who have symptoms at baseline and no symptoms after IMP administration) at the last assessment time point (the day of IMP administration) by Day 7.

Time frame:
Baseline, Day7
Reported as:
Count of participants · Participants
Improvement of or Change in Congestive Findings ( Lower Limb Edema ) From Baseline to Last Assessment Time Point (the Day of IMP Administration) by Day 7
ParticipantsMaterial AMaterial BMaterial CMaterial DPlacebo
Improvement of or Change in Congestive Findings ( Lower Limb Edema ) From Baseline to Last Assessment Time Point (the Day of IMP Administration) by Day 7161891919
SecondaryImprovement of or Change in Congestive Findings ( Pulmonary Congestion ) From Baseline to Last Assessment Time Point (the Day of IMP Administration) by Day 7

The severity of pulmonary congestion will be determined according to the criteria in 0 : Absent, No congestion, 1:Mild,Pulmonary venous congestion, 2:Moderate, Interstitial pulmonary edema, 3 : Severe, Alveolar pulmonary edema. Improvement rates (percentages of subjects who have symptoms at baseline and show markedly improved or improved after IMP administration) and resolution rates (percentages of subjects who have symptoms at baseline and no symptoms after IMP administration) at the last assessment time point (the day of IMP administration) by Day 7.

Time frame:
Baseline, Day7
Reported as:
Count of participants · Participants
Improvement of or Change in Congestive Findings ( Pulmonary Congestion ) From Baseline to Last Assessment Time Point (the Day of IMP Administration) by Day 7
ParticipantsMaterial AMaterial BMaterial CMaterial DPlacebo
Improvement of or Change in Congestive Findings ( Pulmonary Congestion ) From Baseline to Last Assessment Time Point (the Day of IMP Administration) by Day 72119102218

Adverse events

Collected over Adverse events were monitored from signing of the informed consent form until follow-up for up to 10 - 14 days after the last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Material A0/31 (0%)0/31 (0%)11/31 (35.5%)
Material B0/32 (0%)2/32 (6.3%)8/32 (25%)
Material C0/31 (0%)0/31 (0%)12/31 (38.7%)
Material D1/33 (3%)1/33 (3%)14/33 (42.4%)
Placebo1/30 (3.3%)1/30 (3.3%)8/30 (26.7%)
Most frequent serious events
Most frequent serious events
EventMaterial AMaterial BMaterial CMaterial DPlacebo
Cardiac failureCardiac disorders0/310/320/310/331/30
HypernatraemiaMetabolism and nutrition disorders0/310/320/310/331/30
Cerebral infarctionNervous system disorders0/310/320/310/331/30
Angina pectorisCardiac disorders0/311/320/310/330/30
ChondrocalcinosisMusculoskeletal and connective tissue disorders0/311/320/310/330/30
ArrhythmiaCardiac disorders0/310/320/311/330/30
Most frequent other events
Showing 10 of 11
Most frequent other events
EventMaterial AMaterial BMaterial CMaterial DPlacebo
HyperkalaemiaMetabolism and nutrition disorders0/312/325/311/330/30
ConstipationGastrointestinal disorders2/312/324/313/332/30
ThirstGeneral disorders4/314/320/314/330/30
COVID-19Infections and infestations0/310/320/310/333/30
DehydrationMetabolism and nutrition disorders3/311/321/312/330/30
NasopharyngitisInfections and infestations0/310/320/311/332/30
HypotensionVascular disorders1/311/322/311/332/30
Dry mouthGastrointestinal disorders2/310/321/311/330/30
Blood pressure decreasedInvestigations2/310/320/310/330/30
DiarrhoeaGastrointestinal disorders0/311/321/312/331/30

Baseline characteristics

Safety analysis set, which included all randomized patients who received ≥1 dose of the study medication.

Age, Categorical
Age, Categorical(Participants)Material AMaterial BMaterial CMaterial DPlaceboTotal
<=18 years000000
Between 18 and 65 years6533522
>=65 years2527283025135
Age, Continuous
Age, Continuous(Years)Material AMaterial BMaterial CMaterial DPlaceboTotal
Mean73.5 ± 11.675.2 ± 10.775.3 ± 13.176.7 ± 7.976.4 ± 9.475.4 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)Material AMaterial BMaterial CMaterial DPlaceboTotal
Female14192111258
Male171329221899
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Material AMaterial BMaterial CMaterial DPlaceboTotal
American Indian or Alaska Native000000
Asian3132313330157
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White000000
More than one race000000
Unknown or Not Reported000000
08

Study locations

1 site
  • Harasanshin Hospital
    Fukuoka, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Oct 2024, 21 months.

Results were first posted in Oct 2025, 11 months after primary completion.

Of 74 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's 21 months is close to that.

Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2022
First posted
Nov 14, 2022
StartActual
Jan 10, 2023
Primary completionActual
Oct 21, 2024
CompletionActual
Oct 21, 2024
Results first posted
Oct 20, 2025
Last update
Oct 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05615363
Responsible party
Sponsor
First posted
Nov 14, 2022
Start date
Jan 10, 2023
Primary completion
Oct 21, 2024
Completion
Oct 21, 2024
Results posted
Oct 20, 2025
Last update
Oct 20, 2025

Study contacts

Takeshi Tsunoda
study director · Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion